Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Norway to ease COVID-19 curbs, vaccine rollout may be delayed

04/13/2021 | 10:29am EDT
FILE PHOTO: A general view of the Norwegian central bank, where Norway's sovereign wealth fund is situated, in Oslo

OSLO, April 13 (Reuters) - Norway will start to unwind some restrictions related to the COVID-19 pandemic and allow more people to gather from Friday, Prime Minister Erna Solberg said on Tuesday.

However, the country's vaccine rollout risks being delayed by up to almost three months if it does not go ahead and use AstraZeneca and Johnson & Johnson's shots, the Norwegian Institute of Public Health said.

Norway will say on Thursday whether it will resume using the AstraZeneca vaccine, on hold since a small number of younger inoculated people developed a combination of blood clots, bleeding and a low platelet count, some of whom later died.

Johnson & Johnson, meanwhile, said it was delaying the roll-out of its vaccine to Europe as U.S. health agencies recommended pausing its use after six women under 50 given the shot developed rare blood clots.

Norway has had some of Europe's lowest rates of infections and deaths since the start of the pandemic, but imposed stricter measures after a rapid increase in hospitalisations in March triggered by more contagious variants of the coronavirus.

"The infection numbers are now down. Hospitalisations are fewer. The measures look to have had an effect," Solberg told a news conference.

As a result, Norwegians will from Friday again be allowed to receive up to five guests in private homes, up from two currently, and restaurants can serve alcohol under certain conditions.

A maximum of 100 people will be allowed to attend indoor events in for example theaters and sports arenas, provided there are fixed seating arrangements, and groups of up to 200 people can attend outdoor events.

The easing of rules at the national level will not affect those in areas of the Nordic country where the infection rate is the highest, such as in the Oslo capital region, Solberg said.

Non-essential stores remain closed in the Oslo area, and restaurants there are still only allowed to provide takeaway service, and some schools remain shut.

Line Vold, head of infection control and emergency preparedness at the Institute of Public Health, predicted between eight and 12 weeks of delay in vaccinating Norwegians if the AstraZeneca and Johnson & Johnson shots were shunned.

"It will be mainly for the younger groups (in the population). We will be done with vaccination of people in risk groups," she told the same news conference.

The government has said earlier it estimates that everyone aged 18 or older will have been offered their first vaccine shot by the end of July.

(Editing by Mark Heinrich)

© Reuters 2021
All news about ASTRAZENECA PLC
03:50pSECTOR UPDATE : Health Care Stocks Giving Back Most of Wednesday Gains
02:56pHealth Care Flat As Investors Hedge On Growth View -- Health Care Roundup
02:24pMODERNA  : Ontario sees vaccine supply issues, Ottawa keeps AstraZeneca on the m..
01:06pSECTOR UPDATE : Health Care Stocks Narrowly Mixed in Recent Trade
12:18pJ&J vaccine to remain in limbo while officials seek evidence
12:00pASTRAZENECA  : Study Finds Stronger T-Cell Response In Over-80s Dosed With Astra..
11:57aASTRAZENECA  : Canada will not restrict AstraZeneca COVID-19 vaccine, says benef..
11:19aASTRAZENECA  : Europe's vaccine rollout hit by doubts over J&J, AstraZeneca shot..
11:16aASTRAZENECA  : ECB's Lagarde says euro zone economy still on crutches
More news
Financials (USD)
Sales 2021 30 819 M - -
Net income 2021 4 588 M - -
Net Debt 2021 11 699 M - -
P/E ratio 2021 20,3x
Yield 2021 3,92%
Capitalization 95 449 M 132 B -
EV / Sales 2021 3,48x
EV / Sales 2022 2,97x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 129,73 $
Last Close Price 72,71 $
Spread / Highest target 128%
Spread / Average Target 78,4%
Spread / Lowest Target 29,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-2.14%129 245
JOHNSON & JOHNSON1.33%419 864
ROCHE HOLDING AG-0.95%285 584
PFIZER INC.0.43%207 285
NOVARTIS AG-4.61%195 170
MERCK & CO., INC.-6.56%193 467